

Streamlining productspecific bioequivalence guidance


MWP CP-OEG

Carolien Versantvoort, Demy van den Haak



Generics

- In high-in come countries, about 20% of all money spent on health care goes to medicines prescribed.
- The use of generic drugs is an important tool to reduce healthcare spending.






Product specific bioequivalence guidelines (PSBGL)

- First PSBGL in 2009 by PKWP
- Concept paper on the development of product-specific guidance on demonstration of bioequivalence 2013 (EMA/CHMP/423137/2013)
 - Guidance on design of the PK study to demonstrate bioequivalence
 - Stakeholders: generic pharmaceutical industry regulators in the European Union
- Currently 91 PSBGL approved + 2 under public consultation




Current approach of selection of PSBGL products





Proposed approach of choosing PSBGL products





Points for discussion

- The way of proposing products for PSBGL
 - CP-OEG selection based on product characteristics
 - CHMP/CMDh/SAWP requests
 - Generic Pharma Industry
 - Yearly EU survey, collection via MWP stakeholder meeting
 - Yearly open call for a month for generic pharma industry to propose top 5 candidates for PSBGL
 - 5 candidates can be proposed per stakeholder with argumentation
- Number of proposed PSBGL candidates by Pharma
 - The most frequent proposed candidates will be selected with a maximum of 5 candidates
 - Selected candidates will be announced on the designated EMA website: <u>Product-specific</u> <u>bioequivalence guidance | European Medicines Agency (EMA)</u>
 - Number of PSBGL candidates cannot exceed the number of respondents
 - Yearly review of the number of candidates





Thank you

Follow us







